Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Oxaprozin
Drug ID BADD_D01635
Description Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
Indications and Usage Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.
Marketing Status approved
ATC Code M01AE12
DrugBank ID DB00991
KEGG ID D00463
MeSH ID D000077431
PubChem ID 4614
TTD Drug ID D0M9DC
NDC Product Code 60760-092; 63629-8724; 17349-0008; 59762-6002; 0025-1381; 60760-203; 63629-1345; 69238-1120; 61919-178; 61919-673; 71335-0617; 71335-0902; 62135-176; 55111-013; 55111-170; 60760-382; 0185-0141; 55289-601
UNII MHJ80W9LRB
Synonyms Oxaprozin | 4,5-Diphenyl-2-oxazolepropionic Acid | 4,5 Diphenyl 2 oxazolepropionic Acid | Wy-21,743 | Wy 21,743 | Daypro | Rhoxal-oxaprozin | Rhoxal oxaprozin | Apo-Oxaprozin | Apo Oxaprozin | Danoprox | Dayrun
Chemical Information
Molecular Formula C18H15NO3
CAS Registry Number 21256-18-8
SMILES C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.002--
Ulcer08.03.06.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.0010.012890%
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis24.12.04.027; 10.02.02.006--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Tubulointerstitial nephritis20.05.02.002--Not Available
Hypoacusis04.02.01.006--
Emotional distress19.04.02.008--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Protein urine present13.13.02.006--Not Available
Haemorrhoidal haemorrhage24.10.02.001; 07.15.03.002--
Haemorrhage24.07.01.002--Not Available
Weight abnormal13.15.01.016--Not Available
Urine output increased13.13.03.002--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Appetite disorder14.03.01.004; 19.09.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Gastrointestinal ulcer07.04.04.002--Not Available
Ill-defined disorder08.01.03.049--Not Available
Pulmonary function test decreased13.19.01.001--Not Available
Renal impairment20.01.03.010--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages